Here's Why Novo Nordisk Stock Popped Today

Key Points The company's highly promising drug, amycretin, reported impressive results in a trial for Type 2 diabetes. The news follows on for a disappointing, but hardly unexpected, result in a Phase 3 trial for semaglutide in Alzheimer's. 10 stocks we like better than Novo Nordisk › Another day and another release of results from a clinical trial from Novo Nordisk (NYSE: NVO). However, this time it's positive news. Here's the lowdown. Novo Nordisk trial results The pharmaceutical company is best ...